| Name | Title | Contact Details |
|---|---|---|
Alan Smith |
Chief Technology Officer | Profile |
Purigen Biosystems transformative platform provides a hands-free solution for extracting, enriching and quantifying DNA and RNA from biological samples.
VelosBio Inc. is a clinical-stage biopharmaceutical company committed to developing novel, first-in-class, ROR1-directed therapeutics to transform the lives of patients with cancer. Its lead candidate, VLS-101, is a ROR1-directed ADC being developed for patients with hematologic and solid tumor malignancies. The company is developing a broad pipeline of therapeutics targeting ROR1 in oncologic indications with high unmet medical need.
Tranquis Therapeutics is discovering and developing innovative medicines with the potential to revolutionize the management of neurodegenerative and aging-related diseases and to dramatically reduce the burden these illnesses place on patients, families and societies worldwide.
Glympse Bio is developing a powerful new paradigm in diagnostics to enable noninvasive and predictive monitoring of multiple human diseases.
Texcell NA is a Frederick, MD-based company in the Healthcare, Pharmaceuticals, and Biotech sector.